Trials / Completed
CompletedNCT03875157
Study of IBI318 in Participants With Advanced Malignancies
To Evaluate the Safety, Tolerability, and Initial Efficacy of IBI318 in Patients With Advanced Malignancy, Multicenter, IA/IB Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 103 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An open label, multicenter, phase Ia/Ib study to evaluate the safety, tolerability, and initial efficacy of IBI318 in the treatment of patients with advanced malignancies.
Detailed description
An open label, multicenter, phase Ia/Ib study to evaluate the safety, tolerability, and initial efficacy of IBI318 in the treatment of patients with advanced malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IBI318 | 0.3 mg intravenous infusion, C1D1 and afterwards Q2W |
| BIOLOGICAL | IBI318 | 1 mg intravenous infusion, C1D1 and afterwards Q2W |
| BIOLOGICAL | IBI318 | 3 mg intravenous infusion, C1D1 and afterwards Q2W |
| BIOLOGICAL | IBI318 | 10 mg intravenous infusion, C1D1 and afterwards Q2W |
| BIOLOGICAL | IBI318 | 30 mg intravenous infusion, C1D1 and afterwards Q2W |
| BIOLOGICAL | IBI318 | 100 mg intravenous infusion, C1D1 and afterwards Q2W |
| BIOLOGICAL | IBI318 | 300 mg intravenous infusion, C1D1 and afterwards Q2W |
| BIOLOGICAL | IBI318 | 600 mg intravenous infusion, C1D1 and afterwards Q2W |
| BIOLOGICAL | IBI318 | Intravenous infusion, C1D1 and afterwards Q3W |
| BIOLOGICAL | IBI318 | Intravenous infusion, C1D1 and afterwards Q3W |
| BIOLOGICAL | IBI318 | Intravenous infusion Q3W |
Timeline
- Start date
- 2019-04-19
- Primary completion
- 2023-02-16
- Completion
- 2023-02-16
- First posted
- 2019-03-14
- Last updated
- 2023-02-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03875157. Inclusion in this directory is not an endorsement.